Developer docs
API playgroundTry for free, no card

Search company profiles

Aptuit LLC

Full company profile

uuid0009q3c

Namestring
Aptuit LLC
Legal namestring
Evotec
Websiteurl
aptuit.com
Company typeenum
Private
Founded yearint
2004
Descriptiontext

Aptuit LLC is a United States-based contract research organization (CRO) headquartered in Greenwich and founded in 2004, operating with a workforce in the 1,001-5,000 employee band. The firm is positioned as a full-service drug discovery and preclinical development partner for pharmaceutical and biotechnology companies, addressing core client pain points including prolonged discovery timelines, escalating R&D costs, and the integration challenges of personalized medicine and laboratory automation.

The company's service portfolio spans the early R&D value chain. Through organic build and a series of acquisitions completed between 2005 and 2016 - Almedica (2005-07-19), SSCI for solid-state chemistry capabilities (2006-10-01), Exquiron Biotech for biology services (2016-04-21), and Kuecept (2016-05-10) - Aptuit accumulated specialized capabilities in formulation, solid-state chemistry, and discovery biology. A partnership record indicates engagement with Synsight (acquired by Iktos) to integrate the MT Bench system into the drug discovery workflow, dated 2024-07, suggesting the firm is exploring AI-assisted in silico tooling, although no first-party AI platform is documented in the available sources.

The business model follows standard CRO mechanics: fee-for-service and likely FTE-based engagements with pharmaceutical and biotech customers requiring outsourced drug discovery and preclinical development support. Pricing models and per-program contract structures are not publicly disclosed. Customer targeting is horizontal across pharma and biotech rather than vertical-specialized, with the global drug discovery market context (projected at $250.51B by 2030 at a 15.1% CAGR) defining the addressable opportunity. Revenue figures, ownership structure, and detailed financial metrics are not disclosed in the available sources.

Short descriptiontext

Aptuit LLC is a U.S.-based CRO providing drug discovery and preclinical development services, including formulation and solid-state chemistry, to pharmaceutical and biotechnology companies. Founded in 2004 and headquartered in Greenwich, it serves horizontal pharma/biotech R&D outsourcing demand.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersVerona, Italy
HQ citystring
Verona
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
contract research services, drug discovery, preclinical development, pharmaceutical research, medicinal chemistry
Industry3 codes
PRIMARYHLAGAHAG
Impurity / Reference Standard Synthesis & Characterization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Contract Research Organization (CRO) Services
Social media profiles2 records
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Personnel, Operations, Infrastructure, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Just - Evotec Biologics
Description

Biologics Manufacturing - has revolutionized the design, development, and manufacturing of biologics, making high-quality therapies more accessible and affordable

evotec.com
+1 more record
Core offering1 text field

Aptuit LLC is a contract research organization that provides outsourced drug discovery and preclinical development services to pharmaceutical and biotechnology companies. Its offerings span medicinal chemistry, in vitro and in vivo biology, DMPK/ADME, toxicology, formulation, and analytical chemistry to support lead identification, lead optimization, and IND-enabling studies.

Differentiator
Functional benefit
Problem solved
Product and service2 records
1Drug Discovery Services
CategoryContract Research Organization (CRO)
Description

Outsourced drug discovery support for pharmaceutical and biotechnology sponsors, spanning medicinal chemistry, biology, and lead identification/optimization work.

2Preclinical Development Services
CategoryContract Research Organization (CRO)
Description

Preclinical development support covering DMPK/ADME, toxicology, formulation sciences, and analytical chemistry to advance candidates to IND-enabling stages.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Synsight
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-07-01
Description

Iktos, a French pharmaceutical and biotech firm, completed the acquisition of Synsight, a biotechnology company, to integrate Synsight's MT Bench system into its drug discovery platform. Financial terms were not disclosed.

openpr.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Evotec is a global drug discovery and preclinical CRO offering integrated small molecule and biologics services, the closest functional peer to Aptuit's contract research operations; it is also referenced in the company data as an apparent acquirer of Aptuit-like assets.

TypeBroad incumbent
Description

Charles River Laboratories is a broad incumbent CRO/CDMO offering discovery, preclinical, and manufacturing services across small molecules and biologics, overlapping with Aptuit's discovery-to-preclinical scope as part of a much larger portfolio.

TypeBroad incumbent
Description

WuXi AppTec is a leading global CRO/CDMO providing drug discovery, preclinical, and clinical development services with extensive scale in chemistry and biology, a direct competitor for outsourced drug discovery programs served by Aptuit.

TypeBroad incumbent
Description

IQVIA is a major CRO serving biopharma across clinical development and related R&D services; while more weighted to clinical, its R&D Solutions offerings compete with Aptuit's discovery and preclinical positioning.

TypeBroad incumbent
Description

ICON plc is a global CRO with extensive capabilities across clinical and lab services following the PRA Health Sciences merger, competing for outsourced R&D budgets relevant to Aptuit's biopharma clients.

TypeBroad incumbent
Description

Labcorp Drug Development (Covance) provides preclinical, clinical, and central lab services to biopharma, offering a comparable early-phase discovery and development adjacency relevant to Aptuit customers.

TypeBroad incumbent
Description

Syneos Health is a clinical-focused biopharma services provider with preclinical-adjacent offerings, overlapping with Aptuit's customer base of pharmaceutical and biotech sponsors.

TypeBroad incumbent
Description

Medpace is a mid-to-large CRO focused on clinical development for biopharma, sharing the same sponsor customers as Aptuit and competing for share of their outsourced R&D wallet.

TypeDirect peer
Description

Cyprotex is a specialist ADME-Tox and DMPK services provider within the Evotec network, an emerging-niche peer offering preclinical capabilities directly comparable to parts of Aptuit's discovery/preclinical CRO portfolio.

TypeEmerging player
Description

BioDuro is a global CRO/CDMO offering drug discovery, development, and manufacturing services, with growing capacity in medicinal chemistry and biology that directly overlaps with Aptuit's integrated CRO scope.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aptuit LLC

Contract Research Organization (CRO) Servicesaptuit.com

Aptuit LLC is a U.S.-based CRO providing drug discovery and preclinical development services, including formulation and solid-state chemistry, to pharmaceutical and biotechnology companies. Founded in 2004 and headquartered in Greenwich, it serves horizontal pharma/biotech R&D outsourcing demand.

What Aptuit LLC does

Aptuit LLC is a United States-based contract research organization (CRO) headquartered in Greenwich and founded in 2004, operating with a workforce in the 1,001-5,000 employee band. The firm is positioned as a full-service drug discovery and preclinical development partner for pharmaceutical and biotechnology companies, addressing core client pain points including prolonged discovery timelines, escalating R&D costs, and the integration challenges of personalized medicine and laboratory automation.

The company's service portfolio spans the early R&D value chain. Through organic build and a series of acquisitions completed between 2005 and 2016 - Almedica (2005-07-19), SSCI for solid-state chemistry capabilities (2006-10-01), Exquiron Biotech for biology services (2016-04-21), and Kuecept (2016-05-10) - Aptuit accumulated specialized capabilities in formulation, solid-state chemistry, and discovery biology. A partnership record indicates engagement with Synsight (acquired by Iktos) to integrate the MT Bench system into the drug discovery workflow, dated 2024-07, suggesting the firm is exploring AI-assisted in silico tooling, although no first-party AI platform is documented in the available sources.

The business model follows standard CRO mechanics: fee-for-service and likely FTE-based engagements with pharmaceutical and biotech customers requiring outsourced drug discovery and preclinical development support. Pricing models and per-program contract structures are not publicly disclosed. Customer targeting is horizontal across pharma and biotech rather than vertical-specialized, with the global drug discovery market context (projected at $250.51B by 2030 at a 15.1% CAGR) defining the addressable opportunity. Revenue figures, ownership structure, and detailed financial metrics are not disclosed in the available sources.

Aptuit LLC firmographics

Firmographics
Name
Aptuit LLC
Legal name
Evotec
Website
https://aptuit.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Aptuit LLC is a U.S.-based CRO providing drug discovery and preclinical development services, including formulation and solid-state chemistry, to pharmaceutical and biotechnology companies. Founded in 2004 and headquartered in Greenwich, it serves horizontal pharma/biotech R&D outsourcing demand.
Ownership category
akta.pro rank

Aptuit LLC industry classification

Industry
Product category
Contract Research Organization (CRO) Services
NAICS
Scientific Research and Development Services (5417)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAGAHAG
Impurity / Reference Standard Synthesis & Characterization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Contract research services
  • Drug discovery
  • Preclinical development
  • Pharmaceutical research
  • Medicinal chemistry

Where Aptuit LLC is headquartered

Location

Headquarters

HQ city
Verona
HQ country
Italy
HQ region
Europe

Markets served

Aptuit LLC business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D

Marketing channels1 record

Aptuit LLC product offering

Product offering

Core offering

Aptuit LLC is a contract research organization that provides outsourced drug discovery and preclinical development services to pharmaceutical and biotechnology companies. Its offerings span medicinal chemistry, in vitro and in vivo biology, DMPK/ADME, toxicology, formulation, and analytical chemistry to support lead identification, lead optimization, and IND-enabling studies.

Differentiator

Problem solved

Functional benefit

Brands

  • Just - Evotec Biologics: Biologics Manufacturing - has revolutionized the design, development, and manufacturing of biologics, making high-quality therapies more accessible and affordable
  • Cyprotex

Products and services

  • Drug Discovery Services Outsourced drug discovery support for pharmaceutical and biotechnology sponsors, spanning medicinal chemistry, biology, and lead identification/optimization work.
  • Preclinical Development Services Preclinical development support covering DMPK/ADME, toxicology, formulation sciences, and analytical chemistry to advance candidates to IND-enabling stages.

Companies that use Aptuit LLC

Customer profile

Segments1 record

Ideal customer profiles1 record

Aptuit LLC technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Aptuit LLC partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • SynsightcoreTechnology or Integration · 1 July 2024Iktos, a French pharmaceutical and biotech firm, completed the acquisition of Synsight, a biotechnology company, to integrate Synsight's MT Bench system into its drug discovery platform. Financial terms were not disclosed.

Scale indicators1 record

Recent moves5 records

Expansion highlights3 records

Aptuit LLC competitors and assessment

Company assessment

Direct peers

  • Evotec SE: Evotec is a global drug discovery and preclinical CRO offering integrated small molecule and biologics services, the closest functional peer to Aptuit's contract research operations; it is also referenced in the company data as an apparent acquirer of Aptuit-like assets.
  • Cyprotex (Evotec subsidiary): Cyprotex is a specialist ADME-Tox and DMPK services provider within the Evotec network, an emerging-niche peer offering preclinical capabilities directly comparable to parts of Aptuit's discovery/preclinical CRO portfolio.

Broad incumbents

  • Charles River Laboratories: Charles River Laboratories is a broad incumbent CRO/CDMO offering discovery, preclinical, and manufacturing services across small molecules and biologics, overlapping with Aptuit's discovery-to-preclinical scope as part of a much larger portfolio.
  • WuXi AppTec: WuXi AppTec is a leading global CRO/CDMO providing drug discovery, preclinical, and clinical development services with extensive scale in chemistry and biology, a direct competitor for outsourced drug discovery programs served by Aptuit.
  • IQVIA: IQVIA is a major CRO serving biopharma across clinical development and related R&D services; while more weighted to clinical, its R&D Solutions offerings compete with Aptuit's discovery and preclinical positioning.
  • ICON plc: ICON plc is a global CRO with extensive capabilities across clinical and lab services following the PRA Health Sciences merger, competing for outsourced R&D budgets relevant to Aptuit's biopharma clients.
  • Labcorp Drug Development (formerly Covance): Labcorp Drug Development (Covance) provides preclinical, clinical, and central lab services to biopharma, offering a comparable early-phase discovery and development adjacency relevant to Aptuit customers.
  • Syneos Health: Syneos Health is a clinical-focused biopharma services provider with preclinical-adjacent offerings, overlapping with Aptuit's customer base of pharmaceutical and biotech sponsors.
  • Medpace: Medpace is a mid-to-large CRO focused on clinical development for biopharma, sharing the same sponsor customers as Aptuit and competing for share of their outsourced R&D wallet.

Emerging players

  • BioDuro: BioDuro is a global CRO/CDMO offering drug discovery, development, and manufacturing services, with growing capacity in medicinal chemistry and biology that directly overlaps with Aptuit's integrated CRO scope.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Aptuit LLC social profiles

Digital presence

Aptuit LLC financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aptuit LLC leadership team

Management profile

Number of profiles

Profiles1 record

Aptuit LLC funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aptuit LLC M&A and investment

M&A and investment

M&A5 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aptuit LLC

What does Aptuit LLC do?

Aptuit LLC is a contract research organization that provides outsourced drug discovery and preclinical development services to pharmaceutical and biotechnology companies. Its offerings span medicinal chemistry, in vitro and in vivo biology, DMPK/ADME, toxicology, formulation, and analytical chemistry to support lead identification, lead optimization, and IND-enabling studies.

Is Aptuit LLC a public or private company?

Aptuit LLC is a private company. It is classified as venture growth investor backed and is currently operating.

When was Aptuit LLC founded?

Aptuit LLC was founded in 2004. It employs 501 to 1,000 people.

Where is Aptuit LLC based?

Aptuit LLC is headquartered in Verona, Italy, in the Europe region.

Who are Aptuit LLC's main competitors?

Direct peers on record are Evotec SE and Cyprotex (Evotec subsidiary). Broad incumbents are Charles River Laboratories, WuXi AppTec, IQVIA, ICON plc, Labcorp Drug Development (formerly Covance), Syneos Health and Medpace. BioDuro is listed as an emerging player.

Does Aptuit LLC have an API?

No public API is recorded for Aptuit LLC.

What industry is Aptuit LLC in?

Aptuit LLC's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAHAG, Impurity / Reference Standard Synthesis & Characterization, with a secondary code of HLAGAHAL, GMP Scale-Up, Tech Transfer & Process Validation (PPQ). Its NAICS code is 5417 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
news.cision.comCyxone assigns Aptuit for the capsulation of Phase II candidate RabeximodCyxone signed an agreement with Aptuit to capsule Rabeximod for its planned Phase IIb study in rheumatoid arthritis. The work is scheduled to start early next year, with the trial testing the drug's therapeutic effect and safety in patients on methotrexate.PR NewswireAptuit annonce un accord de partenariat stratégique avec Regulus TherapeuticsAptuit announced a strategic partnership with Regulus Therapeutics, covering drug discovery, CMC, and non-clinical services. The agreement supports Regulus's micro-ARN programs, aiming to accelerate development and reduce costs. Both companies highlighted their integrated approach to improve success rates.PR NewswireAptuit anuncia un acuerdo de proveedor estratégico con Regulus TherapeuticsAptuit announced a strategic supplier agreement with Regulus Therapeutics, covering discovery and CMC services for Regulus's microRNA programs. The partnership aims to accelerate Regulus's progress in parallel, with both companies citing efficiency and scientific excellence.PR NewswireAptuit gibt strategischen Lieferantenvertrag mit Regulus Therapeutics bekanntAptuit announced a strategic supplier contract with Regulus Therapeutics to support its microRNA-focused drug development programs. The agreement covers drug research, chemistry manufacturing and controls, and nonclinical services. Both companies expect the partnership to accelerate progress on Regulus's microRNA programs.PR NewswireAptuit Announces Alignment of Organizational Structure to Integrated Solution Delivery: Henning Steinhagen Appointed as President, Research and Development OperationsAptuit LLC appointed Henning Steinhagen as President of Research and Development Operations, consolidating oversight of its global scientific sites in Italy, the UK, and Switzerland. This organizational alignment aims to enhance integrated CMC offerings, shorten timelines, and reduce costs for biopharma partners.PR NewswireAptuit verkündet Ausrichtung der Organisationsstruktur an Bereitstellung integrierter Lösungen: Henning Steinhagen zum President von Research and Development Operations ernanntJonathan Goldman, CEO of Aptuit LLC, announced the appointment of Henning Steinhagen as President of Research and Development Operations, expanding his current role as site manager in Verona, Italy, to include global operational responsibility.PR NewswireAptuit seleccionado como un ganador del premio global Líder de Ciencias de la VidaAptuit, LLC, a contract pharmaceutical manufacturing organization, was selected as a winner of four Contract Manufacturer Organization (CMO) Leadership Awards by Life Science Leader magazine based on a survey of pharmaceutical and biopharmaceutical companies that had outsourced projects in the last 18 months. The company received awards in expertise/experience, quality, and compatibility categories from both Big Pharma and combined Big and Small Pharma survey participants. The awards recognize CMOs that exceeded expectations or performed best in serving their clients in drug discovery, development, manufacturing, and commercialization.PR NewswireAptuit verkündet gemeinsame Arzneimittelforschung mit Massachusetts General Hospital (MGH) zur Identifizierung neuartiger Therapieansätze für gramnegative InfektionenAptuit, LLC announced a joint research collaboration with the Molecular Surgical Laboratory of Massachusetts General Hospital (MGH) led by Dr. Laurence Rahme to identify and validate novel therapeutic targets against gram-negative bacteria. The partnership combines Aptuit's integrated infectious disease research capabilities, including in vitro and in vivo modules, with MGH's antivirulence research expertise to address antibiotic resistance in treating severe infections. The research aims to develop new effective therapeutics against gram-negative pathogens such as Pseudomonas aeruginosa.PR NewswireAptuit annonce une collaboration portant sur la découverte de médicaments avec le Massachusetts General Hospital (MGH) pour identifier de nouveaux traitements pour les infections à bacille gram négatiAptuit, LLC announced a collaboration with the Molecular Surgery Laboratory at Massachusetts General Hospital (MGH), led by Dr. Laurence Rahme, to identify and validate new therapeutic targets in gram-negative bacteria. Aptuit will contribute integrated infectious disease drug discovery expertise, including in vitro and in vivo capabilities, to complement MGH's anti-virulence research platform. The partnership aims to develop alternative treatments for drug-resistant pathogens such as Pseudomonas aeruginosa amid growing antimicrobial resistance concerns.PR NewswireAptuit y Chiesi comienzan un proyecto de descubrimiento integrado para identificar nuevos compuestosAptuit, LLC and Chiesi Farmaceutici announced an agreement on January 4, 2017, to conduct an integrated drug discovery project targeting idiopathic pulmonary fibrosis, a debilitating lung disease. Aptuit will provide primary discovery capabilities including medicinal chemistry, pathology, and pharmacokinetics, while both parties will contribute scientifically to identify promising compounds for preclinical development. The partnership builds on existing relationships between the two companies in the field of respiratory drug discovery, with the goal of progressing compounds with a new mechanism of action toward clinical stages.